Onconius (@onconius) 's Twitter Profile
Onconius

@onconius

La página donde podrás estar al día en Oncología de una forma crítica
The page where you can stay up to date in Oncology in a critical way.

ID: 1664654648400048128

linkhttp://onconius.com calendar_today02-06-2023 15:26:35

52 Tweet

31 Followers

36 Following

Onconius (@onconius) 's Twitter Profile Photo

Inhibidores de PARP (iPARP): nuevos fármacos en el cáncer de próstata resistente a la castración metastásico (CPRCm) onconius.com/blog-1/inhibid…

Tom Powles (@tompowles1) 's Twitter Profile Photo

Subcutaneous atezolizumab (as opposed to IV therapy) is approved in the UK by the MHRA. It’s faster delivery for patients and reduces the increasing burden on systemic therapy units in cancer centres. It’s particularly relevant in the adjuvant setting. england.nhs.uk/2023/08/nhs-wo…

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

The latest update of the MONALEESA-3 trial is just published on BreastCancerResearch, reporting the longest OS to date for 1L patients in a phase 3 ABC trial (median OS with fulvestrant + ribociclib: 67.6 months). …ast-cancer-research.biomedcentral.com/counter/pdf/10…

The latest update of the MONALEESA-3 trial is just published on <a href="/BCRJournal/">BreastCancerResearch</a>, reporting the longest OS to date for 1L patients in a phase 3 ABC trial (median OS with fulvestrant + ribociclib: 67.6 months). 
…ast-cancer-research.biomedcentral.com/counter/pdf/10…
Benjamin Besse (@benjaminbessemd) 's Twitter Profile Photo

Adjuvant alectinib improves DFS vs chemotherapy in pts after resection of a stage IB to IIIA ALK+ NSCLC . Results of phase III trial ALINA spkl.io/60134l8TL. Impact on OS, rate of cross over and brain mets incidence to be followed. Likely to be a new SoC. ALK Positive

Onconius (@onconius) 's Twitter Profile Photo

#Amivantamab y #lazertinib: resultados de los estudios PAPILLON y MARIPOSA #lungcancer #lcsm onconius.com/blog-1/5sttgd5…

Onconius (@onconius) 's Twitter Profile Photo

Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1 - PubMed pubmed.ncbi.nlm.nih.gov/38190035/?utm_…

Onconius (@onconius) 's Twitter Profile Photo

Los anticuerpos conjugados asociados a inmunoterapia llegan a la primera línea de tratamiento en cáncer de vejiga avanzado #emfortumabvedotin #pembrolizumab Astellas Europe Astellas Pharma US MSD España @msd onconius.com/blog-1/los-ant…

Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

Systematic review of TKI efficacy in NSCLC harboring uncommon EGFR mutations JTO & JTO CRR: - 1836pts, 38 studies - G719X, S768I, E709X, L747X; compound mtns; & PACC mtns: best ORR to 2nd-gen TKIs - L861Q best ORR to 3rd gen TKI Alfredo Addeo MD OncoAlert #LCSM jto.org/article/S1556-…

Onconius (@onconius) 's Twitter Profile Photo

#Nivolumab adyuvante mejora la supervivencia global en pacientes con cáncer de vejiga: resultados del estudio CheckMate 274 #EAU24 Matt Galsky onconius.com/blog-1/nivolum…

Onconius (@onconius) 's Twitter Profile Photo

En el podcast de hoy, las oncólogas C. Azpitarte y A. Molina tratarán de diferentes aspectos controvertidos en el tratamiento del cáncer renal Con el patrocinio de Ipsen onconius.com/blog-1/controv…